Short answer
Larimar Therapeutics, Inc. (LRMR) filed an 8-K current report with the SEC on November 16, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Third-quarter fiscal 2026 results announced for period ended September 30, 2026.
Larimar Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Third-quarter fiscal 2026 results announced for period ended September 30, 2026
- Operational highlights included alongside financial results, with details in Exhibit 99.1
- Investor focus: clinical-development progress, cash runway and spending trends disclosed in the accompanying release
Item EX-99.1 · Exhibit EX-99.1
- Completed BLA submission for nomlabofusp, seeking accelerated approval using skin FXN as a potential surrogate endpoint
- FDA acceptance targeted early 2027, with potential U.S. approval mid-2027 and launch targeted Q3 2027
- FORWARD-FA global confirmatory Phase 3 enrolling, creating a key post-submission regulatory and clinical catalyst
- Cash, equivalents and marketable securities $128.7 million at September 30, 2026, runway into late Q2 2027
- Net loss $31.1 million, or $0.29 per share, versus $47.7 million, or $0.61, in Q3 2025; R&D fell to $25.9 million from $44.9 million
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Larimar Therapeutics, Inc. 8-K filings
Get the next LRMR 8-K as it lands
Follow LRMR for push alerts, or ask the research agent what this filing means.